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ABSTRACT 
Objective: Emulsomes are novel vesicular drug delivery system with an internal solid lipid core surrounded by one or more bilayers of 
phospholipids. Etodolac is a potent anti-inflammatory drug and is a drug of choice for the treatment of various diseases. The present study is 
focused on the development of emulsomes using etodolac as drug candidates having improved drug loading with sustained-release effect for patient 
compliance.  
Methods: Emulsomes formulation composed of solid lipids (tristearin), phospholipids, cholesterol, stearylamine, and drug (etodolac) were 
prepared by lipid film hydration method followed by sonication to produce emulsomes of the nanometric size range. All the formulations were 
optimized by using box-behnken design of experiment considering 3 factors viz. drug to phospholipid ratio (A), tristearin to phospholipid ratio (B), 
stearylamine to phospholipid ratio (C) at 3 levels lower (-1), middle (0) and upper (+1). The response of the independent variables (A, B, C) was 
studied on the dependent variable viz. particle size (Y1), zeta potential (Y2), and entrapment efficiency (Y3). The responses were analyzed by design 
expert software to find out the optimized values of variables within the design space.  
Results: Compatibility with excipients was established by FTIR studies. The developed emulsomes were spherical shape vesicles as analyzed by TEM. 
The optimized batch (OB) was evaluated for particle size, zeta potential, and entrapment efficiency with experimental values 383.1 ± 11.7 nm, 47.2 ± 1.3 
mV and 80.1 ± 3.2% and predicted values 390.394 nm, 45.000 mV and 81.642 %, respectively. The experimental values were found in reasonable 
agreement with predicted values by the design of the experiment. In vitro drug release study showed sustained release of the drug (88.69 % after 24 h).  
Conclusion: Etodolac loaded emulsomes is a novel drug delivery system and found to reliable in terms of various characteristic parameters like 
particle size, zeta potential, entrapment efficiency, and drug release. 3-factors 3-levels Box-behnken design of the experiment is a suitable design for 
the optimization of emulsomes. 
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INTRODUCTION 
Lipid-based drug delivery systems have gained the attention of 
researchers in the recent few decades due to their certain 
advantages over other drug delivery systems. Out of various lipid-
based drug delivery system viz. liposomes, solid lipid nanoparticles, 
niosomes, ethosomes, emulsomes, glycerosomes, etc [1, 2]. 
Emulsomes have been proven to be advantageous for the delivery of 
lipophillic drugs. Emulsomes is a lipid-based, vesicular drug delivery 
carrier having structurally similarity with liposomes but differs only 
in core component as emulsomes unlike liposomes is composed of 
solid core [3]. Solid core is composed up of solid lipid which remains 
solid at 25 °C and having solid to liquid phase transition 
temperature near to physiological temperature [4, 5]. Due to lipid 
core, this system becomes advantageous as a carrier system for 
lipophillic drugs having high drug entrapped by encapsulating 
lipophillic drugs in lipid core as well as between phospholipid 
bilayers [6]. Drug entrapped in solid lipid core also exhibits 
sustained release [7]. Charge inducers are also added in emulsomes 
to induce surface charge to the vesicles to prevent aggregation of 
vesicles having a similar charge and stabilize the formulation by 
providing mono-dispersed vesicles [8]. Emulsomes can be used for 
the delivery of drugs via oral, parenteral, rectal, topical, intranasal, 
or ocular [9]. Therefore emulsomes may be considered as an 
efficient drug delivery system because of biocompatibility, 
biodegradability, stability in the gastrointestinal tract, high 
entrapment efficiency, and sustained drug release [10, 11]. 
Etodolac is a non-steroidal anti-inflammatory drug that is used in the 
treatment of rheumatoid arthritis that belongs to pyranocarboxylic 
acid group [12]. Etodolac is a selective COX-2 inhibitor, which is an 
enzyme responsible for the regulation of prostaglandins 
(inflammatory mediators) [13]. Etodolac is a white crystalline powder 
insoluble in water and soluble in alcohols, chloroform, 
dimethylsulfoxide, and polyethylene glycol. It is a very lipophillic drug 
and exists as a racemic mixture of (+) S and (-) R enantiomer. Despite 
its various applications, etodolac causes gastrointestinal disturbances, 
including peptic ulcers and gastrointestinal bleeding, due to these 
problems oral use of etodolac is avoided [14].  
Response surface type designs of experiments have been widely used 
for the optimization of various process parameters for vesicular drug 
delivery systems [15]. The advantage of response surface type designs 
of experiments is that despite using a single factor, multiple factors can 
be studied at a time, including their interaction effect [16]. Various 
types of design using response surface methodology are doehlert 
matrix (DM), box-behnken design (BBD), and central composite design 
(CCD) [17]. Out of this box-behnken design has been mainly used to 
study the effect of 3 factors at 3 levels [18, 19]. In this design quadratic 
equation is generated for evaluating the mathematical relationship 
between independent and dependent variables to study the effect of 
the independent variable on the independent variable [20]. 3-
dimensional response curves and 2-dimensional contour plots help in 
studying the response of 2 factors, including their interaction effect 
keeping other factors constant [17, 21]. 
MATERIALS AND METHODS 
Material 
Etodolac was procured from Balaji chemicals Surat, tristearin, and 
lecithin were procured from HiMedia, cholesterol was procured from 
LOBA chemie Mumbai, sephadex G-50 was procured from Sigma 
aldrich USA, stearylamine was procured from Ottokemi, Mumbai. All 
the other solvents and chemicals used were of analytical grade. 
Method of preparation of emulsomes 
Emulsomes encapsulating etodolac were prepared by the lipid film 
hydration method as described by Gupta and Vyas [10] with slight 
modifications as per laboratory set up. To a 500 ml round bottom flask 
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(RBF) accurately weighed amount of lecithin, tristearin, cholesterol 
and stearylamine were dissolved in a small amount of chloroform. In a 
separate beaker, etodolac was dissolved in methanol. Drug solution in 
methanol was transferred into RBF having other ingredients dissolved 
in chloroform. Both the solutions were mixed and the organic solvent 
was evaporated until complete dryness under reduced pressure using 
a rotary evaporator. Thin dry film was formed over the inner wall of 
RBF. Dry film was hydrated using phosphate buffer saline (pH 7.4). 
Hydration of dry film facilitates swelling of lipids and formation of 
emulsomes vesicles dispersed in the aqueous phase. The solution was 
sonicated by probe sonicator to obtain nano-sized emulsomes vesicles. 
The free un-entrapped drug was removed by passing through 
sephadex G-50 column [22]. 
Optimization of emulsomes formulation 
The formulation was optimized using a box-behnken design of 
experiment, which is a response surface type design of experiment 
wherein responses of 3 factors were studied at 3 levels. Three 
factors considered were phospholipid to etodolac ratio (A); 
phospholipid to tristearin ratio (B) and phospholipid to stearyl 
amine ratio (C) at three levels upper, middle and lower level (+1,0,-
1). A total no. of 17 experiments were designed with 5 center points 
and 12 points at edges of design space for estimation of pure error 
sum of squares to choose the best model among linear, two-factor 
interaction and quadratic model due to the analysis of variance 
(ANOVA), F-value [23]. The effect of independent variables (A, B, C) 
were studied on dependent variables i.e. particle size (Y1), zeta 
potential (Y2) and entrapment efficiency (Y3) by constructing their 
response surface models along with quadratic equation using design 
expert software (Design-expert software, version 11, State-Ease Inc., 
Minneapolis, MN). The designed quadratic polynomial equation 
generated is as follows:  
Y˳ = b˳ + b1X1 + b2X2 + b3X3 + b12X1X2 + b13X1X3 + b23X2X3
+ b11X12 + b22X22 + b33X32 
Where   ˳  is a response for each dependent variable; b˳  is an 
intercept; b1,b2,b3,b12,b13,b23,b11,b22,b33 are regressed 
coefficients from experimental response values of Y; X1, X2, X3 and 
their combinations (X1X2, X1X3, X2X3) and square values (X12, X22, 
X32) represented terms for studying the interactive effect of two 
factors on the response at the same time simultaneously and to 
evaluate the fitness of the model, predicted R2 and adjusted R2. The 
values of independent variables (A, B, C) and the constraints of 
dependent variables (Y1, Y2, Y3) are shown in table 1. 
 
Table 1: Variables used in the box-behnken design of experiment 
 Independent variables Levels 
-1 0 +1 
A = Etodolac to Phospholipid ratio (% w/w of Phospholipid) 1% 3% 5%  
B = Tristearin to Phospholipid ratio (% w/w of Phospholipid) 50% 100% 150% 
C = Stearylamine to Phospholipid ratio (% w/w of Phospholipid) 5% 10% 15% 
Dependent Variables Constraints 
Y1 = Particle Size (nm) Minimum 
Y2 = Zeta Potential (mV) Maximum 
Y3 = Entrapment efficiency (%) Maximum 
 
Drug and excipients compatibility studies 
Etodolac and other ingredients i.e. lecithin, tristearin, stearyl amine, 
and cholesterol were mixed separately in the ratio of 1:1 and all 
ingredients, including drug, were also mixed in equal proportions to 
form a physical mixture. The mixtures were placed in properly sealed 
glass vials and vials were kept at room temperature. The FTIR spectra 
of drug, excipients, and their physical mixtures were recorded and 
analyzed for any deviation in principle peaks of etodolac. The spectra 
of all the samples were analyzed at 4000-600 cm-1. 
Characterization of optimized emulsomes 
Transmission electron microscopy 
The emulsomes were characterized for their shape and surface 
morphology by using a transmission electron microscope 
(TEM)(Hitachi 7500, Japan). Phosphotungstic acid (1 %) was used as 
a negative stain. Carbon coated samples were placed over a copper 
grid and subjected to TEM analysis.  
Particle size and zeta potential measurement 
Emulsomes samples were analyzed in triplicate in an aqueous medium. 
Average particle size and zeta potential were measured at 25 °C by zeta 
sizer (PCS; Zetasizer, HAS 3000; Malvern Instruments, Malvern, UK). All 
the measurements were carried out with an angle of 90 ° at 25 °C [24]. 
Determination of drug entrapment efficiency 
Emulsomes dispersion was drop-wise filtered through sephadex G-
50 column. Filterate was treated with a few drops of triton X-100. 
Triton X-100 breaks the phospholipid bilayer of emulsomes vesicles 
and the entrapped drug comes out in solution, which was analyzed 
by HPLC technique to determine the area under the curve for 
evaluation of entrapped drug [24]. Drug entrapment efficiency was 
calculated using the formula:  
Entrapment ef iciency (%)
=
Amount of drug encapsulated in vesicles
Initial amount of drug taken 
X 100 
In vitro drug release study 
In vitro dissolution studies were performed by the dialysis 
membrane sac technique with the cellophane membrane of 
molecular weight 12000 D [26]. The formulation was placed in a 
dialysis membrane bag and was placed in a vessel having a 
dissolution medium (100 ml). The dissolution medium was 
maintained at a physiological temperature of 37±1 °C with constant 
stirring with a magnetic bead at 50 rpm on the magnetic stirrer 
(REMI, India) [27]. The dialysis membrane sac was hanged in a 
medium. At predetermined intervals (0.5, 1, 2, 4, 6, 8, 10, 12, 24 h) 
the aliquots of 1 ml were taken sink conditions were maintained by 
replacing the equal volume of fresh medium. Samples were analyzed 
for the amount of etodolac released with HPLC method. 
RESULTS AND DISCUSSION 
Drug-excipients compatibility studies 
The drug-excipients compatibility studies were performed by analyzing 
FTIR spectrum of samples for any deviation in principle peaks of the 
drug in the spectrum. As shown in fig. 1 no deviation of principle peaks 
was observed in spectra of etodolac when compared with the various 
spectrum of physical mixtures. Results confirm the physical 
compatibility of the drug with the excipients used in the formulation. 
Preparation and optimization by the box-behnken design of 
experiment 
Etodolac loaded emulsomes were prepared by the lipid film 
hydration method. Based on preliminary studies and experimental 
trial runs, three levels of each independent variable were decided for 
studies. Box-behnken design of the experiment was considered to be 
the best suitable design of the experiment for studying the effect of 
three variables at three levels. On applying the design of the 
experiment using design expert software total of 17 runs with 5 
center points and 12 edge points within the design space were 
obtained [28]. All the 17 batches were prepared and their responses 
were recorded as shown in table 2. It was observed from the 
responses obtained that independent variables (A, B, C) have a 
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significant effect on the dependent variables (particle size, zeta 
potential, entrapment efficiency). Responses obtained from 17 
experimental runs were put in design expert software to obtain 
results fitted to first-order, second-order, and quadratic models 
along with predicted values and conclusion. Responses were 
analyzed for the best fit model with significant quadratic (p<0.0001) 
and insignificant lack of fit (p>0.0525) as shown in table 3. Three 
dimensional (3-D) response curves were generated as shown in fig. 
2. Response curves showed the interaction effect independent 
variables on the dependent variable and useful in studying the effect 
of two factors on one response at a time [15]. Polynomial equations 
were also generated for all three responses (Y1, Y2, Y3). Equations 
helped evaluate the effect of an individual as well as the interaction 
of variables on the responses [17]. A positive sign in the equation for 
a factor represents a synergistic effect on the response, while a 
negative sign represents the antagonistic effect. 
 
 
Fig. 1: Compatibility studies by analysing FTIR spectrum of various samples. (A) Comparison of spectra of etodolac with physical mixture 
(lecithin+etodolac), (B) Comparison of spectra of etodolac with physical mixture (stearylamine+etodolac), (C) Comparison of spectra of 
etodolac with physical mixture (tristearin+etodolac) 
 
Table 2: Experimental layout for 3 factors 3 levels box-behnken design and values of response variables 
Batches Variables Responses 
A B C 
Drug: PHL (in mg) TRI: PHL (in mg) STR: PHL (in mg) Size (nm) Zeta potential (mV) Entrapment efficiency (% 
age) 
F1 1 50 10 206 56.4 69.42 
F2 5 50 10 405 57.4 76.46 
F3 1 150 10 564 52.1 78.67 
F4 5 150 10 641 55.8 88.46 
F5 1 100 5 432 27.8 74.82 
F6 5 100 5 488 28.3 81.67 
F7 1 100 15 651 66.8 73.41 
F8 5 100 15 780 59.3 83.88 
F9 3 50 5 189 22.6 69.68 
F10 3 150 5 492 25.7 75.46 
F11 3 50 15 489 68.5 72.78 
F12 3 150 15 678 64.4 77.67 
F13 3 100 10 378 42.3 80.56 
F14 3 100 10 392 45.5 82.02 
F15 3 100 10 365 44.1 79.96 
F16 3 100 10 388 48.7 81.78 
F17 3 100 10 390 44.8 79.41 
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Table 3: Analysis of variance (ANOVA) of the calculated model for responses 
Result of the ANOVA Particle size (nm) Zeta potential (mV) Entrapment efficiency (%) 
Regression:  
Sum of Squares 4.013E+05 3339.59 358.02 
Degree of freedom (df) 9 9 9 
Mean square 44583.44 371.07 39.78 
F-value 106.99 37.75 26.16 
p-value <0.0001 <0.0001 <0.0001 
Inference  Significant Significant Significant 
Lack of fit tests:  
Sum of squares 2413.75 46.76 5.51 
Degree of freedom (df) 3 3 3 
Mean square 804.58 15.59 1.84 
F-value 6.40 2.83 1.43 
p-value 0.0525 0.1705 0.3575 
Inference  Not significant Not significant Not significant 
Residual:  
Sum of Squares 2916.95 68.81 10.64 
Degree of freedom (df) 7 7 7 
Mean square 416.71 9.83 1.52 
 
   




(B1) (B2) (B3) 
 
  
(C1) (C2) (C3) 
Fig. 2: 3-dimensional response curves showing: (A1) Effect of factors A and B on particle size; (A2) Effect of factors A and C on particle size; 
(A3) Effect of factors B and C on particle size; (B1) Effect of factors A and B on zeta potential; (B2) Effect of factors A and C on zeta 
potential; (B3) Effect of factors B and C on zeta potential; (C1) Effect of factors A and B on entrapment efficiency; (C2) Effect of factors A 
and C on entrapment efficiency; (C3) Effect of factors B and C on entrapment efficiency 
 
The polynomial equation of response Y1 (particle size) is shown as:  
Y1 = 382.60 + 57.63A + 135.75B + 124.63C − 30.50AB + 18.25AC
− 28.50BC + 98.58A2 −  27.18B2 + 106.58C2 
The model F value of 106.99 for particle size implied that the model 
was significant (p<0.0001) with a lack of fit value of 6.40, which was 
not significant (p = 0.0525) [29]. As shown in polynomial equation 
factors A, B, C and interaction of AC have a synergistic effect, while 
the interaction of AB and BC has an antagonistic effect on particle 
size. The predicted R2 value of 0.9025 is justified with an adjusted R2 
value of 0.9835, which indicates the adequacy of the model to 
predict the response of particle size. Adeq. precision measures the 
signal to noise ratio and a ratio greater than 4 is desirable. Adeq. 
precision value 39.289 indicated an adequate signal [30]. 
The polynomial equation of response Y2 (zeta potential) is shown as:  
Y2 = 45.08 − 0.2875A − 0.8625B + 19.33C + 0.6750AB − 2.00AC
− 1.80BC + 5.30A2 + 5.05B2 −  4.83C2 
Gill et al. 
Int J App Pharm, Vol 12, Issue 5, 2020, 166-172 
170 
The model F value of 37.75 for zeta potential implied that the model 
was significant (p<0.0001) with a lack of fit value of 2.83, which was 
not significant (p = 0.1705) [29]. As shown in polynomial equation 
factors C and interaction of AB have a synergistic effect, while factors 
A, B and interactions of AC and BC have an antagonistic effect on zeta 
potential. The predicted R2 value of 0.7704 is justified with an adjusted 
R2 value of 0.9539, which indicates the adequacy of the model to 
predict the response of zeta potential. Adeq. precision measures the 
signal to noise ratio and a ratio greater than 4 is desirable. Adeq. 
precision value 17.7890 indicated an adequate signal [30]. 
The polynomial equation of response Y3 (entrapment efficiency) is 
shown as:  
Y3 = 80.75 + 4.40A + 3.27B + 0.7637C − 0.7475AB + 0.9050AC
− 0.2225BC + 1.162A2 −  3.385B2 −  3.463C2 
The model F value of 26.16 for entrapment efficiency implied that 
the model was significant (p<0.0001) with a lack of fit value of 1.43, 
which was not significant (p = 0.3575) [29]. As shown in polynomial 
equation factors A, B, C and interaction of AC have a synergistic 
effect, while the interaction of AB and BC has an antagonistic effect 
on entrapment efficiency. The predicted R2 value of 0.7389 is 
justified with an adjusted R2 value of 0.9340, which indicates the 
adequacy of the model to predict the response of entrapment 
efficiency. Adeq. precision measures the signal to noise ratio and a 
ratio greater than 4 is desirable. Adeq. precision value 16.7196 
indicated an adequate signal [30]. All the values of various 
parameters of the design about to with concerning responses were 
justified as per design. Therefore this model was used to navigate 
the design space. 
Optimization 
The effects of various variables were studies on the responses and 
the responses were analyzed for different parameters as discussed 
above. Finally, the optimized values of all the three variables 
considered in the study were evaluated by the desirability criteria 
[31]. Desirability criteria in emulsomes formulation were minimum 
particle size with maximum zeta potential and entrapment 
efficiency. The maximum value of desirability is 1 and the values of 
variables having desirability fig. near to 1 are considered to be 
optimized [31] for formulating emulsomes. As evaluated by design 
expert software, the optimized values within design space having 
maximum desirability of 0.797 are selected for formulation shown in 
table 4. 
 
Table 4: Optimized values of variables 
Desirability Optimized value of variables Predicted response 
DRUG: PHL (% 
w/w of PHL) 
TRI: PHL (% 
w/w of PHL) 
STR: PHL (% 







0.797 3.834 90.171 9.689 390.394 45.000 81.642 
 
Surface morphology 
The prepared emulsomes were examined under a transmission 
electron microscope (TEM) for surface morphological studies. The 
image showed that the emulsomes were spherical [9]. All the 
emulsomes vesicles were observed to be mono-dispersed and no 
sign of aggregated vesicles was observed. The TEM image is shown 
in fig. 3. 
 
 
Fig. 3: TEM image of optimized batch (OB) 
 
Particle size and zeta potential 
The average particle size and zeta potential of various batches vary from 
189 nm to 780 nm and 22.6 mV to 68.5 mV, respectively. The average 
particle size and zeta potential of the optimized batch were found to be 
383.1±11.7 nm and 47.2±1.3 mV, respectively (fig. 4 and fig. 5). 
Drug entrapment efficiency 
The samples were analyzed by HPLC method, and the area of 
chromatogram was analyzed to determine the amount of drug 
present in the sample. The drug entrapment efficiency of 
emulsomes batches varies from 69.42 % to 88.46 % and the 
entrapment efficiency of the optimized batch was found to be 
80.1±3.2 %. The high entrapment efficiency was observed in 
emulsomes as compared to other vesicular drug delivery carriers. 
The lipophillic nature of etodolac enhances the high amount of 
drug to be incorporated in between the phospholipid bilayer as 
well as in the solid lipid core of emulsomes [7, 10].  
Thus, more entrapment efficiency was observed. 
In vitro drug release study 
The in vitro drug release study of an optimized batch was carried out 
using a dialysis membrane. The dialysis membrane allows drug 
molecules to diffuse through but restricts the diffusion of 
vesicles [8]. The cumulative drug release during 1
indicated the initial burst release, which may be due to 
 
Fig. 6: In vitro drug release 
CONCLUSION  
Etodolac loaded emulsomes were successfully prepared by 
film hydration method. The formulation was optimiz
box-behnken design of experiment and results revealed that 
behnken design is a suitable design of experiment for optimizing 
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Fig. 5: Zeta potential report 
 
emulsomes 
st hour of 28.45 % 
the initial 
release of drug from the phospholipid bilayer. After 1 h the release 
pattern showed slow release of 
%. The sustained release of drug is due to 
entrapped in solid lipid core composed of tristearin
release study confirms the release of drug in 
to 24 h with a cumulative drug release of 88.69
drug release profile of the optimized batch is shown in 
profile of optimized batch (OB), *values are shown in mean
 
the lipid 
ed by using a 
box-
formulation by considering 3 factors at 3 levels. Results of various 
parameters i.e. particle size (38
(47.2±1.3 mV) and entrapment efficiency (
reasonable agreement with predicted values by 
experiment as particle size (390.394





the drug over 24 h study up to 88.69 
the slow release of drug 
 [25]. The overall 
a controlled manner up 
 %. The cumulative 
fig. 6. 
 
±SD (n = 3) 
3.1±11.7 nm), zeta potential 
80.1±3.2 %) showed 
the design of 
 nm), zeta potential (45.000 
 %). The difference in 
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experimental values and predicted values are not significant, which 
proves the suitability of the box-behnken design of experiment with 
formulation for optimization. In vitro drug release study showed 
sustained release of the drug throughout for 24 h. Thus it can be 
concluded that emulsomes are promising drug delivery system for 
lipophillic drugs like etodolac with better entrapment efficiency and 
sustained drug release, which can be optimized by box-behnken 
design of experiment.  
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